Search

Displaying results 8051 - 8060 of 8515 in total
  1. Drug

    Trifluoroethanol

    go.drugbank.com/drugs/DB03226
    Experimental

    A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.

  2. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.

  3. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib has a monoisotopic molecular weight of 442.21 Da.

  4. Drug

    Zavacorilant

    go.drugbank.com/drugs/DB21509
    Investigational

    Zavacorilant has a monoisotopic molecular weight of 555.15 Da.

  5. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da.

  6. Drug

    Neladalkib

    go.drugbank.com/drugs/DB21712
    Investigational

    Neladalkib has a monoisotopic molecular weight of 452.15 Da.

  7. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.

  8. Drug

    Finotonlimab

    go.drugbank.com/drugs/DB18859
    Investigational

    Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).

  9. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    The partial clinical hold was later lifted in May 2021.

  10. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).